ReviewBest practice & research. Clinical rheumatology2022
Calcinosis in dermatomyositis: Origins and possible therapeutic avenues.
Review in Best practice & research. Clinical rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Advances in the clinical applications of sodium thiosulphate.Annals of medicine · 2026Review
- Extensive dystrophic calcinosis in dermatomyositis with concurrent breast carcinoma: an imaging pitfall.Radiology case reports · 2026Article
- Liquefied Calcinosis Cutis Mimicking an Abscess in a Clinically Inactive Anti-MDA5 Antibody Positive Juvenile Dermatomyositis.International journal of rheumatic diseases · 2026Article
- Spatial transcriptomic profiling reveals fibroblast and inflammatory signatures in calcinosis of chronic cutaneous lupus.JID innovations : skin science from molecules to population health · 2026Article
- Early detection and intervention in dermatomyositis: current evidence and clinical implications.Clinical rheumatology · 2026Review
- Calcinosis Cutis Universalis: A Review of Therapeutic Strategies and Surgical Management.Journal of clinical medicine · 2026Review
- Reversibility of calcinosis in anti-NXP2-positive refractory dermatomyositis treated with TNF-α blockade: a brief report.Frontiers in medicine · 2026Article
- Tissue calcinosis in dermatomyositis - potential role of combination therapy with JAK inhibitors. Case report and literature review.Frontiers in immunology · 2026Review
- Dermatomyositis: Prevalence, Clinical Spectrum, Diagnostic Approach, and Management Strategies.Archives of internal medicine research · 2026Article
- Long-term management challenges in postmyopathic dermatomyositis.Dermatology online journal · 2025Article
- Calcinosis Cutis Presenting as Multiple Discharging Sinuses in Skin: A Case Report.JNMA; journal of the Nepal Medical Association · 2025Article
- Article
- Calcinosis Universalis: An Atypical Presentation of Mi-2 Positive Juvenile Dermatomyositis - A Case-Based Review.Mediterranean journal of rheumatology · 2025Article
- Clinical Image: Extensive subcutaneous calcinosis cutis with fistulization in refractory dermatomyositis.ACR open rheumatology · 2025Article
- Calcinosis in dermatomyositis.Current opinion in rheumatology · 2024Review
- Treatment of Calcinosis in Dermatomyositis-Case Report and Review.Journal of clinical medicine · 2024Article
- Calcinosis in Rheumatic Disease Is Still an Unmet Need: A Retrospective Single-Center Study.Diagnostics (Basel, Switzerland) · 2024Article
- Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population.Clinical rheumatology · 2023Article
- Role of mitochondria in the myopathy of juvenile dermatomyositis and implications for skeletal muscle calcinosis.Journal of autoimmunity · 2023Article
- Calcinosis in juvenile dermatomyositis: Updates on pathogenesis and treatment.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Calcinosis, insoluble calcium compounds deposited in skin and other tissues, is a crippling sequela of dermatomyositis. Prolonged disease associated with ongoing inflammation, ischemia, repetitive trauma, and certain autoantibodies are associated with calcinosis. Herein, we describe potential pathogenic mechanisms including the role of mitochondrial calcification. There are no widely effective treatments for calcinosis. We review available pharmacologic therapies for calcinosis including those targeting calcium and phosphorus metabolism; immunosuppressive/anti-inflammatory therapies; and vasodilators. Mounting evidence supports the use of various formulations of sodium thiosulfate in the treatment of calcinosis. Although the early institution of aggressive immunosuppression may prevent calcinosis in juvenile dermatomyositis, only limited data support improvement once it has developed. Minocycline can be useful particularly for lesions associated with surrounding inflammation. Powerful vasodilators, such as prostacyclin analogs, may have promise in the treatment of calcinosis, but further studies are necessary. Surgical removal of lesions when amenable is our treatment of choice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.